LRRK2-IN-1 is a pyrimidobenzodiazepine, specifically 5,11-dimethylpyrimido[4,5-b][1,4]benzodiazepin-6-one, bearing at C-2 of the pyrimidine ring a 4-[(4-methylpiperazin-1-yl)piperidine-1-carbonyl]-2-methoxyanilino substituent. It inhibits the LRRK2 kinase associated with Parkinson's disease and acts as an EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor and antineoplastic agent. It is classified as an N-acylpiperidine, N-alkylpiperazine, aromatic ether, aromatic amine, secondary amino compound, and tertiary amino compound.
